Arcutis outlines $480M-$495M 2026 revenue guidance while expanding ZORYVE sales teams
Arcutis Biotherapeutics, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $21.47
-3.0% in 7d after detection
Post-detection moves
1h
—
1d
+2.5%
3d
+0.1%
7d
-3.0%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS